Lymphoma Canada is here to support healthcare professionals as they provide the best care possible to lymphoma patients.
Resources Designed for You
This algorithm-based tool will help Canadian physicians understand, adopt and apply the current Canadian Evidence-based Guideline for the First-line Treatment of Follicular Lymphoma in clinical practice.
The recommendations and supporting evidence have been synthesized into an easy-to-navigate visula map format. Simply click on a node, or box, within an algorithm to view a summary of relevant information and access slide resources, if available.
Clinician Participation in the pCODR Process
The CADTH pan-Canadian Oncology Drug Review (pCODR) reviews cancer drugs and provides funding recommendations to Canada’s provinces and territories (except Quebec). Funders use this information in their decision-making process to determine if a drug will be eligible for public reimbursement.
Learn more about the value of clinician input to the pCODR process from Dr. Joseph Connors: Clinician Participation in the pCODR Process
Input from registered clinicians (practising oncologists or physicians who treat cancer patients, oncology pharmacists, oncology nurses) is collected to gain insight into local clinical practices and identify areas of unmet need. Oncologists or physicians who treat cancer patients can provide their input as an individual submission or jointly in a group submission. Oncology pharmacists and oncology nurses provide invaluable information on drug preparation and administration, and are eligible to provide input as part of a joint submission with a lead oncologist.
Consult our FACT SHEET for information on how to register and provide input and feedback as a clinician.
Canadian researchers and healthcare professionals are invited to apply to Lymphoma Canada’s 2019 Research Grants Program:
The Lymphoma Canada Research Awards are intended to support small, well-defined research studies that have the potential to effect improvements in healthcare, health systems, or health outcomes for malignant lymphoproliferative diseases.
Each award consists of a one-time payment, to a maximum of $25,000, dependent on the nature of the research study.
More information can be found here.
Are you looking for information to share with patients on their diagnosis and care? You can order patient-friendly resources here.